Large Study Finds Prenatal Cannabis Exposure Was Not Independently Linked to Childhood Anxiety or Depression

 A large retrospective study found that prenatal cannabis exposure was not independently associated with an increased risk of childhood anxiety or depressive disorders after researchers adjusted for maternal health, other substance use and demographic factors.

Researchers examining health records from more than 115,000 children found that prenatal cannabis exposure was not independently associated with a greater risk of early-onset anxiety or depressive disorders after key confounding factors were taken into account.

The findings, first highlighted in an August 6 report from National NORML, add important context to an area of research frequently shaped by alarming headlines, incomplete data and difficulty separating cannabis exposure from other factors that may influence childhood mental health.

The study does not establish that cannabis use during pregnancy is safe. It also does not prove that cannabis protects children from anxiety. Instead, it suggests that prenatal cannabis exposure, by itself, did not explain an increased incidence of anxiety or depression diagnoses among the children included in this large cohort.

What did the prenatal cannabis study examine?

Researchers affiliated with Kaiser Permanente Northern California and the University of California, San Francisco conducted a population-based retrospective cohort study involving 115,553 children born to 97,376 pregnant patients between 2011 and 2017.

Participants receiving prenatal care were universally screened for cannabis use at approximately eight to 10 weeks of pregnancy. Exposure was identified through self-report, a urine toxicology test for THC, or both. Researchers then used electronic health records to track clinician-documented anxiety and depressive disorders in the children from ages six through 13.

That design gave the study several strengths. It included a large and diverse population, used both self-reporting and toxicology screening, and examined clinical diagnoses rather than relying exclusively on questionnaires about symptoms.

The researchers also adjusted their analysis for factors that could independently affect a child’s mental health, including maternal anxiety and depressive disorders before pregnancy, use of non-cannabis substances during early pregnancy, demographic characteristics and maternal medical conditions.

What did researchers find?

In the unadjusted analysis, prenatal cannabis exposure appeared to be associated with an increased risk of childhood depressive disorders. Once researchers accounted for relevant covariates, however, that association was no longer statistically significant.

The fully adjusted hazard ratio for depressive disorders was 1.15, with a 95 percent confidence interval of 0.85 to 1.54. Because that interval includes 1.0, the result does not demonstrate a statistically significant increase in risk.

For anxiety disorders, prenatal cannabis exposure was associated with a modestly lower rate of diagnosis after adjustment, with an adjusted hazard ratio of 0.84. However, the study’s authors cautioned against interpreting that association as evidence that prenatal cannabis exposure prevents anxiety.

The apparent lower rate could reflect differences that the available data could not fully measure. Possibilities include family environment, parenting behavior, healthcare utilization, willingness to report symptoms or other unmeasured characteristics. The inverse association also appeared when exposure was identified by toxicology testing, but not when it was defined only through self-report.

The responsible conclusion is therefore narrower: this study did not find evidence that prenatal cannabis use independently increased the risk of a diagnosed anxiety or depressive disorder during childhood.

Why controlling for confounding factors matters

Observational cannabis research is complicated because people who use cannabis during pregnancy may differ from people who do not in ways that also influence health outcomes.

Maternal mental health is one important example. A pregnant patient may use cannabis in an attempt to manage anxiety, stress, nausea, pain or another condition. Those underlying conditions—and not necessarily cannabis exposure—may themselves be associated with later outcomes for the child.

Tobacco, alcohol and other substance use can also affect pregnancy and childhood development. Socioeconomic conditions, access to healthcare, genetics, stress and family support may further influence both cannabis use and the likelihood that a child receives a mental-health diagnosis.

That is why the difference between an unadjusted association and an adjusted result is so important. In this study, the initial association with depression weakened after researchers accounted for those overlapping variables, suggesting that common underlying factors may have driven the raw correlation.

In plain language: two things occurring together does not prove that one caused the other.

What the findings do—and do not—tell us

The study adds meaningful evidence to the discussion of prenatal cannabis exposure and childhood mental health, but its scope was specific. Researchers examined cannabis exposure during early pregnancy and diagnoses of anxiety and depression between ages six and 13.

It did not settle questions involving every possible pregnancy, birth or developmental outcome. Nor could it fully measure the timing, duration, method of consumption, cannabinoid content or potency of the cannabis products used.

The authors called for additional research examining whether outcomes vary based on those factors. Longer follow-up will also be necessary to evaluate diagnoses that emerge later in adolescence or adulthood.

Current public-health guidance has not changed as a result of this study. The Centers for Disease Control and Prevention discourages cannabis use during pregnancy and advises anyone who is pregnant, planning a pregnancy or breastfeeding to discuss cannabis use with a healthcare professional.

This distinction matters. Accurate reporting should neither exaggerate the harms found in a study nor stretch a limited finding into a declaration of safety.

Better cannabis policy begins with better evidence

For decades, cannabis policy has often moved faster than cannabis science—and political messaging has frequently treated correlation as causation. Large, carefully adjusted studies help produce a more accurate understanding of what the evidence actually shows.

This research does not close the conversation about cannabis and pregnancy. It does challenge the claim that prenatal exposure was independently associated with higher rates of childhood anxiety or depression in this population.

Suncoast NORML supports continued research, honest risk communication and public policy grounded in evidence rather than stigma. Patients deserve clear information that acknowledges both what researchers have learned and what remains uncertain.

Pregnant patients should speak openly with a qualified healthcare provider about cannabis, medications and any symptoms they are attempting to manage. Medical decisions should be individualized and based on the best available evidence—not fear, shame or an oversimplified headline.

Frequently Asked Questions

Does prenatal cannabis exposure cause childhood anxiety or depression?

In this study, prenatal cannabis exposure was not independently associated with an increased risk of clinician-diagnosed anxiety or depressive disorders in children ages six to 13 after researchers adjusted for key confounding factors.

Did the study prove that cannabis use during pregnancy is safe?

No. The study examined two childhood mental-health outcomes and did not evaluate every potential pregnancy, birth or developmental effect. Its findings should not be interpreted as proof of overall safety.

Why did the unadjusted and adjusted results differ?

The unadjusted data did not fully account for other factors associated with childhood mental health. After researchers considered maternal mental health, other substance use, demographic characteristics and health conditions, the apparent increase in depression risk was no longer statistically significant.

Does the lower adjusted anxiety rate mean prenatal cannabis prevents anxiety?

No. The study was observational and cannot establish a protective effect. The finding may reflect unmeasured differences in behavior, family environment, symptom reporting or healthcare use.

Where was the original report published?

National NORML summarized the research in its article, “Analysis: Prenatal Cannabis Exposure Not Independently Associated With Elevated Risk of Child Depressive Disorders or Anxiety.” The underlying peer-reviewed study, “Cannabis Use During Early Pregnancy and Child Diagnoses of Depressive and Anxiety Disorders,” appeared in Cannabis, the journal of the Research Society on Marijuana.

This article is for educational and informational purposes only and is not medical advice. Anyone who is pregnant, planning to become pregnant or breastfeeding should consult a qualified healthcare professional before using cannabis or changing any treatment.